The study is for patients 70 years and older who are newly diagnosed with suspected ovarian, fallopian tube, primary peritoneal carcinomas or advanced stage papillary serous uterine carcinoma. Using a brief modified version of the Comprehensive Geriatric Assessment Survey (CGAS) at the pre-operative stage and some blood work, Gynecologic Oncologists would derive a score from a predictive model and follow these patients prospectively through non randomized treatment (both surgery and chemotherapy).
The “investigational drug” AZD1775 is being combined with standard chemotherapy in subjects with TP53-mutated, advanced ovarian, fallopian tube or peritoneum cancer that no longer responds to platinum therapy. AZD1775 is also being studied in lung cancer and ovarian cancer and other solid tumors. Some ovarian cancer patients have experienced tumor shrinkage while receiving AZD1775 plus chemotherapy.